NovoRapid contains the active substance insulin aspart, a rapid-acting insulin.
Diabetes is a disease in which the body does not produce enough insulin to control the level of blood glucose. NovoRapid is a replacement insulin that is very similar to the insulin made by the body but is absorbed faster by the body. This allows it to start acting faster than human insulin. The replacement insulin works in the same way as naturally produced insulin and helps glucose enter cells from the blood. By controlling the level of blood glucose, the symptoms and complications of diabetes are reduced.
The Agency’s Committee for Medicinal Products for Human Use (CHMP) decided that NovoRapid’s benefits are greater than its risks and recommended that it be given marketing authorisation.